Objective: To observe the clinical application of olopatadine eye drops alone or combination with pranoprofen eye drops in the treatment of allergic conjunctivitis (AC). The levels of serum immunoglobulin, histamine (...Objective: To observe the clinical application of olopatadine eye drops alone or combination with pranoprofen eye drops in the treatment of allergic conjunctivitis (AC). The levels of serum immunoglobulin, histamine (HA) and eosinophil cationic protein (ECP) were analyzed. Methods: A total of 90 AC patients were randomly divided into control group (n=45) and observation group (n=45) according to the lottery method. The control group was treated with olopatadine hydrochloride eye drops. On the basis of the control group, the observation group was treated with pranoprofen eye drops. The levels of serum immunoglobulin, HA and ECP were measured in all subjects. Results: There was no significant difference in serum immunoglobulin level between the observation group and the control group before treatment. After treatment, the levels of serum IgG, IgA and IgE in the observation group and the control group were significantly lower than those before treatment. And the observation group was significantly lower than the control group after treatment. There were no significant differences in serum HA and ECP levels between the observation group and the control group before treatment. After treatment, the levels of serum HA and ECP in the observation group and the control group were significantly lower than those before treatment. And the observation group was significantly lower than the control group after treatment. Conclusion: Compared with olopatadine eye drops, olopatadine eye drops combined with pranoprofen eye drops in the treatment of AC patients, can effectively reduce the serum immunoglobulin, HA and ECP levels, which may be the clinical treatment of AC patients Of the effective reference program.展开更多
Purpose:To evaluate the efficacy and safety of pranoprofen eye drops for reducing postoperative ocular pain and inflammation after corneal cross-linking (CXL). Methods:Twenty-seven patients (38 eyes) with keratoconus ...Purpose:To evaluate the efficacy and safety of pranoprofen eye drops for reducing postoperative ocular pain and inflammation after corneal cross-linking (CXL). Methods:Twenty-seven patients (38 eyes) with keratoconus undergoing CXL were examined and randomly divided into control (12 cases; 18 eyes) and experimental groups (15 cases;20 eyes).The patients in the control group were given fluorometholone eye drops,and those in the experimental group were administered with fluorometholone combined with pranoprofen eye drops.Corneal irritation and haze were compared between the two groups at 1 month postoperatively. Results:At 1 to 3 days after surgery,the corneal irritation in the experimental group was significantly reduced compared with that in the control group (P<0.05), but there was no significant difference on 5 to 7 days postoperatively (P>0.05). The average degree of haze in the experimental group was significantly lower than that in the control group 1 month after surgery (P<0.05), but there was no significant difference in the best-corrected vision acuity and intraocular pressure between the two groups. There were 2 cases with >20 mmHg intraocular pressure in the control group. Conclusion:The combined use of fluorometholone and pranoprofen can significantly reduce inflammatory response,alleviate corneal irritation at early stage after CXL,effectively prevent and control the average of haze,and reduce the incidence of steroid-induced ocular hypertension after surgery.展开更多
目的系统评价普拉洛芬治疗白内障术后干眼的临床疗效。方法计算机检索中国知网、万方医学网、维普资讯中文期刊服务平台、Web of Science、中国生物医学文献服务系统(CBM)、PubMed、Cochrane Library数据库中有关普拉洛芬治疗白内障术...目的系统评价普拉洛芬治疗白内障术后干眼的临床疗效。方法计算机检索中国知网、万方医学网、维普资讯中文期刊服务平台、Web of Science、中国生物医学文献服务系统(CBM)、PubMed、Cochrane Library数据库中有关普拉洛芬治疗白内障术后干眼的随机对照试验。对照组使用玻璃酸钠滴眼液,试验组在使用玻璃酸钠滴眼液基础上使用普拉洛芬滴眼液,检索时限为2018年1月至2023年11月。由2名研究者独立筛选文献、提取相关资料并按照Cochrane系统评价员手册进行质量评价,采用Review Manager5.3软件及STATA12.0统计软件进行数据分析及异质性检验。结果共纳入文献18篇,2318例患者。试验组总有效率明显高于对照组[优势比(OR)=8.529,95%可信区间(95%CI)5.53~13.15,P<0.001];泪膜破裂时间明显长于对照组[加权均数差(WMD)=2.60,95%CI 2.09~3.11,P<0.001];泪液分泌量明显高于对照组(WMD=1.98,95%CI 1.66~2.30,P<0.01);角膜荧光素染色评分、干眼症状评分均明显低于对照组(WMD=-0.93、-1.55,95%CI-1.23~-0.63、-2.18~-0.92,P<0.001)。结论普拉洛芬治疗白内障术后干眼的疗效优于人工泪液,能提高临床有效率,延长患者泪膜破裂时间,增加泪液分泌量,降低角膜荧光素染色,改善干眼症状。展开更多
目的观察普拉洛芬滴眼液联合0.1%玻璃酸钠滴眼液治疗干眼患者的临床疗效。方法选择2014年7月—2015年6月就诊于新疆医科大学第一附属医院眼科门诊、符合纳入标准的干眼患者235例(280眼)。随机分为联合用药组(142眼)和单纯用药组(138眼)...目的观察普拉洛芬滴眼液联合0.1%玻璃酸钠滴眼液治疗干眼患者的临床疗效。方法选择2014年7月—2015年6月就诊于新疆医科大学第一附属医院眼科门诊、符合纳入标准的干眼患者235例(280眼)。随机分为联合用药组(142眼)和单纯用药组(138眼),对联合用药组给予普拉洛芬滴眼液联合0.1%玻璃酸钠滴眼液治疗,单纯用药组给予0.1%玻璃酸钠滴眼液治疗,用药前和用药1个月后对纳入对象进行标准干眼症状评估(SPEED)问卷评分调查,并对两组患者的泪膜破裂时间(BUT)、角膜荧光素染色(FLS)、泪液分泌功能(Schirmer I试验)进行检查和比较。结果用药后两组患者自觉症状及临床症状均较用药前有所改善,联合用药组及单纯用药组治疗后标准干眼症状评估(SPEED)问卷评分差异有统计学意义(t=2.25,P=0.03),治疗后联合用药组较单纯用药组泪膜破裂时间(BUT)增加,差异有统计学意义(t=3.00,P=0.00),联合用药组治疗后较单纯用药组治疗后角膜荧光染色(FLS)改善更明显,差异有统计学意义(t=3.58,P=0.00),而两组干眼病人用药后泪液分泌功能(Schirmer I test)差异无统计学意义(t=0.87,P=0.16>0.05)。结论普拉洛芬滴眼液联合0.1%玻璃酸钠滴眼液治疗干眼较单独使用0.1%玻璃酸钠滴眼液治疗干眼的临床疗效好。展开更多
文摘Objective: To observe the clinical application of olopatadine eye drops alone or combination with pranoprofen eye drops in the treatment of allergic conjunctivitis (AC). The levels of serum immunoglobulin, histamine (HA) and eosinophil cationic protein (ECP) were analyzed. Methods: A total of 90 AC patients were randomly divided into control group (n=45) and observation group (n=45) according to the lottery method. The control group was treated with olopatadine hydrochloride eye drops. On the basis of the control group, the observation group was treated with pranoprofen eye drops. The levels of serum immunoglobulin, HA and ECP were measured in all subjects. Results: There was no significant difference in serum immunoglobulin level between the observation group and the control group before treatment. After treatment, the levels of serum IgG, IgA and IgE in the observation group and the control group were significantly lower than those before treatment. And the observation group was significantly lower than the control group after treatment. There were no significant differences in serum HA and ECP levels between the observation group and the control group before treatment. After treatment, the levels of serum HA and ECP in the observation group and the control group were significantly lower than those before treatment. And the observation group was significantly lower than the control group after treatment. Conclusion: Compared with olopatadine eye drops, olopatadine eye drops combined with pranoprofen eye drops in the treatment of AC patients, can effectively reduce the serum immunoglobulin, HA and ECP levels, which may be the clinical treatment of AC patients Of the effective reference program.
文摘Purpose:To evaluate the efficacy and safety of pranoprofen eye drops for reducing postoperative ocular pain and inflammation after corneal cross-linking (CXL). Methods:Twenty-seven patients (38 eyes) with keratoconus undergoing CXL were examined and randomly divided into control (12 cases; 18 eyes) and experimental groups (15 cases;20 eyes).The patients in the control group were given fluorometholone eye drops,and those in the experimental group were administered with fluorometholone combined with pranoprofen eye drops.Corneal irritation and haze were compared between the two groups at 1 month postoperatively. Results:At 1 to 3 days after surgery,the corneal irritation in the experimental group was significantly reduced compared with that in the control group (P<0.05), but there was no significant difference on 5 to 7 days postoperatively (P>0.05). The average degree of haze in the experimental group was significantly lower than that in the control group 1 month after surgery (P<0.05), but there was no significant difference in the best-corrected vision acuity and intraocular pressure between the two groups. There were 2 cases with >20 mmHg intraocular pressure in the control group. Conclusion:The combined use of fluorometholone and pranoprofen can significantly reduce inflammatory response,alleviate corneal irritation at early stage after CXL,effectively prevent and control the average of haze,and reduce the incidence of steroid-induced ocular hypertension after surgery.
文摘目的观察普拉洛芬滴眼液联合0.1%玻璃酸钠滴眼液治疗干眼患者的临床疗效。方法选择2014年7月—2015年6月就诊于新疆医科大学第一附属医院眼科门诊、符合纳入标准的干眼患者235例(280眼)。随机分为联合用药组(142眼)和单纯用药组(138眼),对联合用药组给予普拉洛芬滴眼液联合0.1%玻璃酸钠滴眼液治疗,单纯用药组给予0.1%玻璃酸钠滴眼液治疗,用药前和用药1个月后对纳入对象进行标准干眼症状评估(SPEED)问卷评分调查,并对两组患者的泪膜破裂时间(BUT)、角膜荧光素染色(FLS)、泪液分泌功能(Schirmer I试验)进行检查和比较。结果用药后两组患者自觉症状及临床症状均较用药前有所改善,联合用药组及单纯用药组治疗后标准干眼症状评估(SPEED)问卷评分差异有统计学意义(t=2.25,P=0.03),治疗后联合用药组较单纯用药组泪膜破裂时间(BUT)增加,差异有统计学意义(t=3.00,P=0.00),联合用药组治疗后较单纯用药组治疗后角膜荧光染色(FLS)改善更明显,差异有统计学意义(t=3.58,P=0.00),而两组干眼病人用药后泪液分泌功能(Schirmer I test)差异无统计学意义(t=0.87,P=0.16>0.05)。结论普拉洛芬滴眼液联合0.1%玻璃酸钠滴眼液治疗干眼较单独使用0.1%玻璃酸钠滴眼液治疗干眼的临床疗效好。
